Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Frances Wang 2025 Jul 06, 16:00

Stock market today: Dow, S&P 500, Nasdaq futures fall, Sensex, Nifty update

Stocks Indices
Frances Wang 2025 Jul 06, 16:00

Lumber Stocks to Watch: SSD stock, UFPI stock, HD stock

Stocks
Frances Wang 2025 Jul 06, 16:00

Oil Price Is Under $70: Where is Oil Price Expected to Go?

Commodities
Tommy Yap 2025 Jul 06, 16:00

Morning Note: Dollar Near Lows on Tariffs; US Eyes AI Chip Curbs; Ethereum’s Future

Morning Note Forex Cryptocurrencies
monetary Policy
Tommy Yap 2025 Jul 05, 21:00

Week Ahead: Monetary Policy Focus Turns to RBA and RBNZ

Forex Indices
Ghko B 2025 Jul 03, 16:00

Solana Price Gains 4%: What is the price target for Solana?

Cryptocurrencies
Frances Wang 2025 Jul 03, 16:00

Bitcoin Price Outlook: What will be the value of Bitcoin in 2025?

Cryptocurrencies
Tommy Yap 2025 Jul 03, 16:00

Morning Note: Markets Break Records - What’s Fueling the Surge?

Morning Note Stocks S&P 500 Forex Oil CPI

Info

Spread

0.06

Spread (%)

1.1450 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Senin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

747867584

Saham yang Beredar

138238000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.23

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot